tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

ERAS Stock Latest News

Erasca’s Innovative RAS/MAPK Pathway Targeting and Promising Preclinical Data Earns Buy Rating
RatingsErasca’s Innovative RAS/MAPK Pathway Targeting and Promising Preclinical Data Earns Buy Rating
9d ago
ERAS
Erasca presents new RAS-targeting franchise data at AACR meeting
PremiumThe Fly
Erasca presents new RAS-targeting franchise data at AACR meeting
9d ago
ERAS
Erasca initiated with an Outperform at Raymond James
PremiumThe Fly
Erasca initiated with an Outperform at Raymond James
1M ago
ERAS
RVMD
Erasca’s Innovative RAS Platform: A Buy Rating for Potential Best-in-Class Therapeutics
PremiumRatings
Erasca’s Innovative RAS Platform: A Buy Rating for Potential Best-in-Class Therapeutics
2M ago
ERAS
Promising Clinical Developments and Strategic Acquisitions Drive Buy Rating for Naporafenib and Molecular Glue Assets
PremiumRatings
Promising Clinical Developments and Strategic Acquisitions Drive Buy Rating for Naporafenib and Molecular Glue Assets
2M ago
ERAS
Erasca, Inc. Reports 2024 Financial and Strategic Progress
PremiumCompany AnnouncementsErasca, Inc. Reports 2024 Financial and Strategic Progress
2M ago
ERAS
Erasca reports Q4 EPS (11c), consensus (13c)
Premium
The Fly
Erasca reports Q4 EPS (11c), consensus (13c)
2M ago
ERAS
ERAS Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ERAS Earnings this Week: How Will it Perform?
2M ago
ERAS
Erasca assumed with an Overweight at Morgan Stanley
PremiumThe Fly
Erasca assumed with an Overweight at Morgan Stanley
2M ago
ERAS
Erasca’s Promising Oncology Advances: Buy Rating Backed by Strong Market Potential and Competitive Edge
PremiumRatings
Erasca’s Promising Oncology Advances: Buy Rating Backed by Strong Market Potential and Competitive Edge
2M ago
ERAS
Erasca Highlights Strategic Focus at Healthcare Conference
PremiumCompany Announcements
Erasca Highlights Strategic Focus at Healthcare Conference
4M ago
8K
ERAS
Erasca upgraded to Buy from Neutral at BofA
PremiumThe Fly
Erasca upgraded to Buy from Neutral at BofA
4M ago
ERAS
Erasca initiated with a Buy at Jefferies
PremiumThe FlyErasca initiated with a Buy at Jefferies
6M ago
ERAS
RVMD
Erasca, Inc. Reports Strong Progress in Oncology Pipeline
Premium
Company Announcements
Erasca, Inc. Reports Strong Progress in Oncology Pipeline
6M ago
ERAS
Erasca reports Q3 EPS (11c), consensus (17c)
Premium
The Fly
Erasca reports Q3 EPS (11c), consensus (17c)
6M ago
ERAS
Erasca announces clinical progress for naporafenib
PremiumThe Fly
Erasca announces clinical progress for naporafenib
7M ago
ERAS
Erasca to present preliminary SEACRAFT-1 Phase 1 data
PremiumThe Fly
Erasca to present preliminary SEACRAFT-1 Phase 1 data
8M ago
ERAS
Erasca participates in a conference call with JPMorgan
PremiumThe Fly
Erasca participates in a conference call with JPMorgan
8M ago
ERAS
Erasca price target raised to $6 from $5 at H.C. Wainwright
PremiumThe Fly
Erasca price target raised to $6 from $5 at H.C. Wainwright
9M ago
ERAS
Erasca reports Q2 EPS (29c), consensus (18c)
PremiumThe FlyErasca reports Q2 EPS (29c), consensus (18c)
9M ago
ERAS
Erasca initiates SEACRAFT-2 Phase 3 trial of naporafenib plus trametinib
Premium
The Fly
Erasca initiates SEACRAFT-2 Phase 3 trial of naporafenib plus trametinib
11M ago
ERAS
Erasca price target lowered to $5 from $8 at H.C. Wainwright
Premium
The Fly
Erasca price target lowered to $5 from $8 at H.C. Wainwright
12M ago
ERAS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >